In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MG Biotherapeutics Inc.

Latest From MG Biotherapeutics Inc.

Medtronic: Doing Just What the Doctors Order

Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
Medical Device Business Strategies

Medtronic: Making Convergence Pay

Medtronic has been a pioneer in drug/device convergence: creating products whose therapeutic benefit stems equally from the features of their drug and device components. Convergence represents one of the medical device industry's most promising opportunities. But getting past the cultural differences between medical device and biotech companies can be huge.
BioPharmaceutical Medical Device

Gauging the Risks of Financing Convergence Start-Ups

A handful of recent biotech-device company deals have highlighted the potential of drug-device convergence as natural extensions of the ever-popular repurposing and drug delivery models espoused by investors aiming to reduce the risks associated with drug discovery. Venture capitalists are eager to get in on the game, but drug and device hybrid business models are few and far between. True convergence start-ups remain thin on the ground, a fact VCs say reflects the additive nature of drug risk and device risk.
BioPharmaceutical Medical Device

Cardio3: Moving from Science Project to Business Model in Stem Cells

Cardiac stem cell therapy for regenerating diseased heart tissue has been long on promise but short on delivery. A Belgian incubator and start-up hope to finally bring this treatment to market.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MG Biotherapeutics Inc.
  • Senior Management
  • Contact Info
  • MG Biotherapeutics Inc.
    710 Medtronic Pkwy. NE
    Minneapolis, MN 55432
    USA
UsernamePublicRestriction

Register